Among the hypoglycemic drugs approved for the T2D treatment [38], SGLT2 inhibitors (SGLT2i) are gaining increasing attention due to their proven cardio-renal efficacy. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.